Stock SYNT SYNTHETICMR AB
Add to a list
To use this feature you must be a member
Log inSign up

SyntheticMR AB Share Price

Equities

SYNT

SE0015987946

Advanced Medical Equipment & Technology

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 04:30:00 31/01/2024 am IST 		5-day change 1st Jan Change
27.7 SEK +1.09% Intraday chart for SyntheticMR AB -.--% +4.14%
17/04 SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities CI
27/03 SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D CI

Financials

Sales 2024 * 112M 10.23M 853M Sales 2025 * 145M 13.26M 1.11B Capitalization 1.15B 106M 8.8B
Net income 2024 * 22M 2.01M 168M Net income 2025 * 39M 3.56M 297M EV / Sales 2024 * 10.1 x
Net cash position 2024 * 28.42M 2.6M 217M Net cash position 2025 * 44.3M 4.05M 338M EV / Sales 2025 * 7.65 x
P/E ratio 2024 *
50.5 x
P/E ratio 2025 *
29.2 x
Employees 37
Yield 2024 *
0.72%
Yield 2025 *
1.08%
Free-Float 42.6%
More Fundamentals * Assessed data

Chart SyntheticMR AB

Dynamic Chart

Latest news about SyntheticMR AB

SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities CI
SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D CI
Royal Philips Partners SyntheticMR to Roll Out New Brain Disorder Diagnosis Technology MT
SyntheticMR AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
SyntheticMR AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking CI
SyntheticMR Receives Order from an OEM Partner CI
SyntheticMR Extends Partnership with Philips to Include SyMRI 3D MT
SyntheticMR and Philips Announces Expands Global Partnership for SyMRI 3D CI
SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance CI
SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting CI
SyntheticMR AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SyntheticMR AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11 CI
SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow CI
More news

Press releases SyntheticMR AB

Notice to attend the annual general meeting of SyntheticMR AB (publ) AQ
SyntheticMR publishes annual report for 2023 AQ
SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR's SyMRI NEURO Software at SimonMed Facilities. AQ
SyntheticMR : and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR’s SyMRI NEURO Software at SimonMed Facilities PU
SyntheticMR receives FDA 510(k) clearance for their next Generation Solution SyMRI 3D AQ
More press releases

Quotes and Performance

1 day+1.09%
3 months+2.59%
6 months+41.69%
Current year+4.14%
More quotes

Highs and lows

Current year
25.00
Extreme 25
31.70
1 year
17.30
Extreme 17.3
34.90
3 years
17.30
Extreme 17.3
79.40
5 years
11.70
Extreme 11.7
79.40
10 years
2.76
Extreme 2.76
79.40
More quotes

Managers and Directors - SyntheticMR AB

Managers TitleAgeSince
Ulrik Harrysson CEO
 Chief Executive Officer 55 01/19/01
Jan Bertus Marten Warntjes FOU
 Founder 51 16/07/16
Johanna Norén DFI
 Director of Finance/CFO 50 01/21/01
Members of the board TitleAgeSince
Karl Staffan Persson BRD
 Director/Board Member 68 01/13/01
Ann-Christine Sundell BRD
 Director/Board Member 60 -
Jan Bertus Marten Warntjes FOU
 Founder 51 16/07/16
More insiders

Company Profile

SyntheticMR AB (publ) is a Sweden-based company that develops and markets software solutions for Magnetic Resonance Imaging (MRI). The Company provides SyMRI, which measures the absolute properties of the brain and delivers adjustable contrast images, automatic biomarker segmentation and quantitative data in a single MR scan. The SyMRI product is available in different packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps, parametric common contrast weighted images and maps of the brain, allowing the investigation to be taken even further. SyMRI is a registered trademark in Europe and in the USA.
Sector
Advanced Medical Equipment & Technology
Calendar
20/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for SyntheticMR AB

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
27.7 SEK
Average target price
30 SEK
Spread / Average Target
+8.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
SYNTHETICMR AB Stock SyntheticMR AB
+4.14% 105M
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
SECTRA AB Stock Sectra AB
+22.93% 3.89B
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. SYNT Stock